TipRanks
The race for vaccination against COVID-19 variants is heating up; 3 shares to consider
Let’s talk about the economy and COVID-19. Normally, this is a topic that will dwell on the economic catastrophe of the past year – the sharp recession last winter, the sharp rise in unemployment, the unprecedented rise in government debt. All of these are important, even urgent topics for discussion, but we are here to talk about vaccines and opportunities. Specifically the vaccines that come from the biotechnology sector, and the opportunities it will offer. The rapid spread of COVID around the world has led to great pressure from the Big Pharma industry to create a working vaccine for the disease – a pressure that has achieved successful results. Two working vaccines were in production before the end of 2020 and reached the general public. Several other vaccine manufacturers developed or approved products in the early months of this year. It was an impressive display of medical and technological expertise put to the benefit of the public. However, the advent of vaccines has not calmed the COVID pandemic. As this virus has mutated, and new variants begin to spread. The existing vaccines may be effective, but they may not – and just as we get a new flu shot every year, we can look at a situation where we need our usual ‘corona boosters’ around the changing variants of the virus. And now we come to the part where we talk about the middle ground. A global vaccination program, and new vaccines for new strains, provides a great business for biopharmaceutical companies engaged in vaccine research and production. Using the TipRanks database, we have shown the details of three biopharmaceutical companies that will be profitable as the vaccination possibilities expand. Novavax, Inc. (NVAX) We start in the DC suburbs, where the Novavax-based Gaithersburg, Maryland, is a specialist biotechnology firm focusing on the development of vaccines for respiratory diseases. The company was involved in previous work on the SARS and MERS viral outbreaks, which uniquely adapted it in advance for work on the COVID-19 agent; both the SARS and MERS viruses come from the same class of coronaviruses as COVID-19. Earlier this month, Novavax reported that its COVID-19 vaccination program had completed Phase 3 trials and demonstrated an efficacy of 96.4% against the original strain of the virus. In addition, the Novavax vaccine is also in a phase 2b trial against the South African variant of the virus. The company announced that data from the trial show an effectiveness of 55.4% against the South African tribe, in patients who are HIV-negative. In both studies, the vaccine candidate achieved his statistical goals, including 100% protection against serious diseases and hospitalization. 5-star analyst Mayank Mamtani, who covers these shares for B. Riley Securities, takes note of the company’s successful vaccination trials and considers them the surest way forward for Novavax. “NVAX [is] ‘ahead of the marathon in building a durable vaccine franchise, mainly by designing a candidate for an increased vaccine that could also include their candidates for the late-stage C-19 vaccine and flu,’ Mamtani said. . The analyst added: ‘We continue to believe recent stock volatility offers another attractive opportunity to accumulate NVAX shares, especially in light of a fierce catalyst profile made up of several approvals regulators worldwide, starting with repeated guidance for the MHRA filing in early 2Q and the U.S. FDA filing within 2Q. “For this purpose, Mamtani rates NVAX shares as a buy, and its price target of $ 397 implies an upward potential of 74% for the coming year. (To view Mamtani’s record, click here. Overall, Wall Street votes analysts agree NVAX is a good prospect for investors, all 5 recent reviews are here to buy, which makes Strong Buy’s consensus rating unanimous, with shares trading at $ 201.50 and the average price target of $ 307.40 indicates that the upward one-year is about 35%. (See NVAX stock analysis on TipRanks) VBI vaccines (VBIV) The next COVID fighter we are looking at is VBI Vaccines, another company that specializes in vaccine research and The company has a history of chronic viral diseases, such as hepatitis B, which is difficult to treat, but has also worked with other coronaviruses in the past.The big news here appeared earlier this month when VBI and CEPI (Coali tion for Epidemic Preparedness Innovations) jointly announced a partnership to use VBI’s vaccine candidates in research against the B.1.351 variant of the COVID-19 virus. It is the South African variant and is known to be more resistant to existing treatments. The development of a vaccine against this strain is an important step forward against the COVID-19 pandemic. The partnership has $ 33 million in funding for the VBI adaptation of its encapsulated virus-like particle (eVLP) vaccine technology against the South African variant. VBI’s eVLP technology has already been tested in preclinical studies against SARS-CoV-2 (the COVID-19 drug), and has promised to induce antibody titers against all three variants. In addition, the vaccine candidate showed response to HCoV-OC43, one of the already known seasonal coronaviruses. All of this attracted the attention of Raymond James analyst Steven Seedhouse. ‘Partnership with CEPI, together with our macro-thesis on COVID (that is, that the virus is endemic and that different vaccines plus annual boost years are needed for years or even forever), VBI is jointly advocating for a significant increase in the profile of its COVID vaccine programs. and more broadly, its key organization (CEPI) eVLP platform, which today also announced a $ 3.5 billion initiative to reduce vaccine timelines for future pandemics, ‘Seedhouse said. Seedhouse sets a $ 9 price target on this stock, showing confidence in a solid upward 159% upside for the next 12 months, and supporting its strong buy rating. (Click here to see the performance history of Seedhouse.) Overall, we’re looking at a stock with a unanimous consensus from Wall Street analysts – four judges weighed in and everyone posted a rating here for a strong buy rating. VBIV shares are trading at $ 3.47, and the average price target of $ 6.75 indicates room for 94% growth this year. (See VBIV stock analysis on TipRanks) Moderna, Inc. (MRNA) Moderna made headlines in the news as it was one of the first two companies, along with Pfizer, to release an effective COVID-19 vaccine on the market. The shot of Moderna – a two-dose vaccine based on mRNA technology – has been in the news since November, and the company’s share has soared 480% over the past twelve months. From the beginning of the vaccination programs, there have been questions and concerns about the possibility of booster shots. Will they be needed, will they be safe, will they increase efficiency? Modern is working to answer these questions, and on March 10, the company announced that it had begun dosing patients for the study of COVID boosters, in an amendment to the ongoing Phase 2 trials. The share has risen by more than 9% since the announcement. Moderna’s stimulant announcement highlights an unusual feature of the COVID vaccine development program, which is visible everywhere. The vaccines move rapidly through the development process. This is partly due to the ability of companies to build on previous work with regard to SARS and MERS, and partly due to development programs such as the fact that Moderna pushed the vaccine candidates through separate parts of the development and clinical trial phase at the same time. . Moderna’s generation program will test the current vaccine and vaccine candidates against different strains of the new coronavirus. In a note for Brookline Capital, analyst Leah Rush Cann Moderna looks at a long-term path to increased sales and profits, which stems directly from the company’s success with the COVID-19 vaccine program. The analyst writes that the ‘announcement for progress with a variant-addressed COVID-19 vaccine supports our conviction for our prospect that mRNA-1273, and potentially alternative vaccines or enhancers, could have sales of $ 51.4 billion by 2030 and 51 % of Moderna’s revenue from 2030 … “The analyst added:” We still believe that the Moderna COVID-19 vaccine has increasingly better properties, and that it reaffirms the flexibility and power of mRNA platforms; so that they can adapt very quickly to variations and mutations in infectious diseases. Consistent with her comments, Cann is looking to buy the stock, and its target price of $ 205 indicates that growth will reach 32% over the next 12 months. (To check out Cann’s, click here. Debates over the vaccines are reflected in stock debates, and Moderna has a mix of reviews from Wall Street analysts. Of the 13 reviews in the file, 6 are 5 to hold, 5 to hold and 2 to sell, making the consensus rating a moderate buy.The average price target is $ 168.08, which implies that the trade price of $ 155 is an increase of 8%. (Consult MRNA stock analysis on TipRanks.) To find great ideas for stocks that are trading at attractive valuations, visit TipRanks’ best stocks to buy, a newly launched tool that unites all TipRanks stocks. this article is pronounced solely that of the proposed analysts.The content is for informational purposes only.It is very important to do your own analysis before investing.